Genetic Variation of the Vitamin D Binding Protein Affects Vitamin D Status and Response to Supplementation in Infants.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

To study GC genotype-related differences in 25OHD concentrations and the response to supplementation during a vitamin D intervention study in infants.

Why It Was Studied

Single nucleotide polymorphisms (SNPs) of the vitamin D binding protein encoding the GC (group component) gene affect 25-hydroxyvitamin D (25OHD) concentrations, but their influence on vitamin D status and response to vitamin D supplementation in infants is unknown.

Who Took Part

PubMed indexes the participants as infants, both men and women.

How the Study Was Run

The researchers set it up as a randomized and double-blind study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

GC SNPs rs2282679, rs4588, rs7041, and rs1155563 were genotyped. rs4588/7041 diplotype and haplotypes of rs2282679, rs4588, and rs7041 (Haplo3SNP) and of all four SNPs (Haplo4SNP) were determined.

What Was Measured

The subject headings attached to it are Alleles, Cholecalciferol, Genotype, Haplotypes, Polymorphism, Single Nucleotide, Vitamin D and Vitamin D-Binding Protein.

What This Means in Plain Language

The paper is a randomized and double-blind study of Vitamin D, K2, Magnesium and Zinc.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2019 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.